{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:31:46Z","timestamp":1753893106296,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"DOI":"10.3389\/frph.2020.618838","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T06:44:48Z","timestamp":1611125088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Future of Luteal Phase Support in ART and the Role of Dydrogesterone"],"prefix":"10.3389","volume":"2","author":[{"given":"Panagiotis","family":"Drakopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Roelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Mackens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AnnaLisa","family":"Racca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Tournaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Blockeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI(dagger)","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open."},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/humrep\/15.1.43","article-title":"Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization","volume":"15","author":"Beckers","year":"2000","journal-title":"Hum Reproduct."},{"key":"B3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.rbmo.2019.05.001","article-title":"Weekly intramuscular progesterone for luteal phase support in women receiving oocyte donation is associated with a decreased miscarriage rate","volume":"39","author":"Delcour","year":"2019","journal-title":"Reproduct Biomed Online."},{"key":"B4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0015-0282(16)56935-0","article-title":"Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study","volume":"62","author":"Miles","year":"1994","journal-title":"Fertility Sterility."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/humrep\/12.5.1073","article-title":"Targeted drug delivery in gynaecology: the first uterine pass effect","volume":"12","author":"Bulletti","year":"1997","journal-title":"Hum Reproduct."},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/humupd\/5.4.365","article-title":"Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus","volume":"5","author":"Cicinelli","year":"1999","journal-title":"Hum Reproduct Update."},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD009154","DOI":"10.1002\/14651858.CD009154.pub3","article-title":"Luteal phase support for assisted reproduction cycles","volume":"2015","author":"van der Linden","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/humrep\/dex316","article-title":"Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study","volume":"32","author":"Labarta","year":"2017","journal-title":"Hum Reproduct."},{"key":"B9","first-page":"724","article-title":"Isopregnenone (Duphaston): a new progestational agent","volume":"19","author":"Backer","year":"1962","journal-title":"Obstet Gynecol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.maturitas.2009.10.011","article-title":"Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium","volume":"65","author":"Schindler","year":"2009","journal-title":"Maturitas."},{"key":"B11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.steroids.2011.02.043","article-title":"Selectivity and potency of the retroprogesterone dydrogesterone in vitro","volume":"76","author":"Rizner","year":"2011","journal-title":"Steroids."},{"key":"B12","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/09513590.2019.1706085","article-title":"The role of progestogen supplementation (dydrogesterone) in the prevention of preeclampsia","volume":"36","author":"Tskhay","year":"2020","journal-title":"Gynecol. Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1515\/hmbci-2015-0063","article-title":"Dydrogesterone support following assisted reproductive technique (ART) reduces the risk of pre-eclampsia","volume":"27","author":"Ali","year":"2016","journal-title":"Horm Mol Biol Clin Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.fertnstert.2011.01.148","article-title":"Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study","volume":"95","author":"Ganesh","year":"2011","journal-title":"Fertility Sterility."},{"key":"B15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jsbmb.2005.08.012","article-title":"Oral dydrogesterone vs. intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study","volume":"97","author":"Chakravarty","year":"2005","journal-title":"J Steroid Biochem Mol Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejogrb.2014.11.002","article-title":"Oral dydrogesterone vs. vaginal progesterone gel in the luteal phase support: randomized controlled trial","volume":"186","author":"Tomic","year":"2015","journal-title":"Eur J Obstetr Gynecol Reproduct Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/humrep\/dex266","article-title":"A phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone vs. micronized vaginal progesterone for luteal support in in vitro fertilization","volume":"32","author":"Tournaye","year":"2017","journal-title":"Hum Reproduct."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1093\/humrep\/dey306","article-title":"Oral dydrogesterone vs. intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial","volume":"33","author":"Griesinger","year":"2018","journal-title":"Hum Reproduct."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/humupd\/dmy033","article-title":"Fresh vs. elective frozen embryo transfer in IVF\/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes","volume":"25","author":"Roque","year":"2019","journal-title":"Hum Reproduct Update."},{"key":"B20","doi-asserted-by":"publisher","first-page":"CD003414","DOI":"10.1002\/14651858.CD003414.pub3","article-title":"Cycle regimens for frozen-thawed embryo transfer","volume":"7","author":"Ghobara","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B21","first-page":"861","article-title":"[Effects of oral dydrogesterone on clinical outcomes of frozen-thawed embryo transfer cycles]","volume":"33","author":"Guo","year":"2013","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao."},{"key":"B22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00404-016-4217-4","article-title":"Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial","volume":"295","author":"Zarei","year":"2017","journal-title":"Arch Gynecol Obstet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.apjr.2016.10.002","article-title":"Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: a pilot randomized controlled trial","volume":"5","author":"Rashidi","year":"2016","journal-title":"Asian Pacific J Reproduct."},{"key":"B24","first-page":"i442","article-title":"Oral dydrogesterone vs. micronized vaginal progesterone for artificial frozen-thawed embryo transfer cycles","volume":"34","author":"Alahmad","year":"2019","journal-title":"Hum Reproduct."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas."},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.rbmo.2018.11.017","article-title":"Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction","volume":"38","author":"Griesinger","year":"2019","journal-title":"Reproduct Biomed Online."},{"key":"B27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/HYPERTENSIONAHA.118.12043","article-title":"Increased preeclampsia risk and reduced aortic compliance with in vitro fertilization cycles in the absence of a corpus luteum","volume":"73","author":"von","year":"2019","journal-title":"Hypertension."}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2020.618838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T06:44:50Z","timestamp":1611125090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2020.618838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":28,"alternative-id":["10.3389\/frph.2020.618838"],"URL":"https:\/\/doi.org\/10.3389\/frph.2020.618838","relation":{},"ISSN":["2673-3153"],"issn-type":[{"type":"electronic","value":"2673-3153"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"article-number":"618838"}}